Search results
Validation of the MIRACLE2 Score
Author(s):
Nicholas Sunderland
,
Francine Cheese
,
Zoe Leadbetter
,
et al
Added:
1 year ago
Article
Author(s):
Biykem Bozkurt
Added:
1 year ago
Author(s):
Added:
8 months ago
TIMELY is an integrated AI-based healthcare solution consisting of a certified physician platform and a patient app. It has been developed within an EU-funded project running from 2021 to 2025. TIMELY aims to assist both cardiac patients and their clinicians in personalising healthcare by evaluating risks and offering individualised exercise recommendations. The solution has been evaluated within…
View more
Added:
4 months ago
Source:
Radcliffe Cardiology
AUTHOR: Greg GuilloryThe selection of drug-eluting stents (DES) for percutaneous coronary intervention (PCI) involves balancing efficacy against safety. The SORT OUT XI randomised trial aimed to compare a newer-generation biolimus-eluting stent with a contemporary dual-therapy sirolimus-eluting stent in a real-world patient population, providing crucial head-to-head evidence.¹SORT OUT XI was a…
View more
Author(s):
Carolina Álvarez-Ortega
,
Josué Daniel Gómez-Martínez
,
María Alejandra Cardona-Gallardo
,
et al
Added:
1 year ago
Author(s):
Mark Anderson
,
Nicolas Brozzi
,
Raul Rosenthal
,
et al
Added:
1 year ago
Added:
3 months ago
Source:
Radcliffe Cardiology
For patients with suspected angina with non-obstructive coronary arteries (ANOCA) or ischaemia with non-obstructive coronary arteries (INOCA), the diagnostic pathway can be challenging. A new study suggests that while exercise electrocardiography stress testing (EST) has limited ability to confirm underlying microvascular disease, its high negative predictive value makes it a valuable tool for…
View more
Author(s):
Brian Lindman
Added:
7 months ago
ACC 2025 - Primary findings from EARLY-TAVR show the benefit of early TAVR intervention was consistent across biomarker subgroups.Dr Brian Lindman (Vanderbilt University Medical Center, Nashville, US) joins us onsite at ACC 2025 to discuss findings from the primary biomarker analysis from the EARLY TAVR trial (NCT03042104; Edwards Lifesciences). The analysis investigated cardiac biomarkers in…
View more
Author(s):
Peter Frederiksen
,
Ann Banke
Added:
1 year ago